A recent study presented at the annual meeting of the American Diabetes Association has revealed exciting findings about a new treatment option for people with insulin-naive type 2 diabetes.
The study compares the effectiveness of once-weekly icodec to once-daily insulin degludec in reducing hemoglobin A1c (HbA1c) levels.
This article aims to explain the study’s findings in simple language for 11-year-old kids who may not be familiar with scientific terms.
Understanding Type 2 Diabetes
Type 2 diabetes is a condition where the body has trouble using insulin properly or doesn’t produce enough insulin.
Insulin is a hormone that helps control blood sugar levels. People with type 2 diabetes need to manage their blood sugar levels to stay healthy.
Dr. Ildiko Lingvay and her team from the University of Texas Southwestern Medical Center conducted a phase 3a trial involving 294 participants from 92 sites across 11 countries.
The participants were randomly assigned to receive either once-weekly icodec and once-daily placebo or once-daily insulin degludec and once-weekly placebo.
Better Blood Sugar Control
The researchers found that the mean HbA1c levels, which indicate long-term blood sugar control, decreased in both groups.
However, the decrease was greater in the once-weekly icodec group, going from 8.6% to 7.0% compared to the degludec group, which went from 8.5% to 7.2%.
This means that once-weekly icodec was superior to once-daily insulin degludec in reducing HbA1c levels.
Other Factors
The study also looked at other factors like fasting plasma glucose (blood sugar levels after not eating for a while), weekly insulin dose, and changes in body weight. The results showed no significant differences between the two groups in these areas.
It means that both treatments were similar in controlling fasting plasma glucose, insulin dose, and weight changes.
Managing Hypoglycemia
Hypoglycemia, or low blood sugar, is a potential side effect of diabetes treatments. The study found that the once-weekly icodec group had slightly higher rates of hypoglycemia compared to the degludec group.
This means that people using once-weekly icodec experienced low blood sugar more often. However, it’s important to note that the difference was small and needs to be weighed against the benefits of once-weekly administration.
The study showed that once-weekly icodec is an effective treatment option for people with insulin-naive type 2 diabetes. It demonstrated better control of HbA1c levels compared to once-daily insulin degludec.
Although the icodec group had slightly higher rates of hypoglycemia, the convenience of once-weekly administration may outweigh this small risk.
Important Considerations
It’s essential to remember that this study was funded by Novo Nordisk, the pharmaceutical company that manufactures once-weekly insulin icodec.
Some of the researchers involved in the study also have connections to pharmaceutical companies. It’s always important to consider multiple sources of information and consult healthcare professionals to make informed decisions about diabetes treatment.
Taking Care of Your Health
If you or someone you know has type 2 diabetes, it’s crucial to work closely with doctors and diabetes care teams to manage the condition effectively.
Diabetes treatment options continue to evolve, and advancements like once-weekly icodec offer hope for improved blood sugar control and convenience. With the right support and guidance, people with diabetes can lead healthy and fulfilling lives.
If you care about diabetes, please read studies about a cure for type 2 diabetes, and why insulin is more expensive for people with diabetes.
For more information about diabetes, please see recent studies about bone drugs that could lower the risk of type 2 diabetes, and results showing eating more eggs is linked to a higher risk of type 2 diabetes.
The study was published in JAMA.
Copyright © 2023 Knowridge Science Report. All rights reserved.
